- Home
- SGLY vs SCNX Comparison
SGLY vs SCNX Comparison
Compare SGLY & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$0.45
Company Overview
Basic Information| Metric | SGLY | SCNX |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | | Other Pharmaceuticals |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 19.0M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGLY | SCNX |
|---|---|---|
| Price | $0.39 | $0.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 15.1K | ★ 2.2M |
| Earning Date | 02-13-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,813,193.00 | N/A |
| Revenue This Year | N/A | $347.88 |
| Revenue Next Year | N/A | $744.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $0.37 |
| 52 Week High | $1.86 | $2.60 |
Technical Indicators
Market Signals| Indicator | SGLY | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 50.43 |
| Support Level | $0.38 | $0.39 |
| Resistance Level | $0.43 | $0.47 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 10.00 | 36.90 |
Price Performance
Historical Comparison SGLY
SCNX
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.